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Breast cancer annually afflicts over half a million women (Pisani
et al, 1999). Androgens play an important role in the development
and progression of breast cancer (Secreto et al, 1983; Oriana et al,
1987). Increased serum levels of androgens correlate with an
increased likelihood of disease (Grattarola, 1973; Grattarola et al,
1974; Key and Pike, 1988). Nearly 60% of women with breast
cancer show some degree of hypertestosteronaemia (Secreto et al,
1983). Excessive production of testosterone has also been reported
in women with atypical breast duct hyperplasia, a precursor of
breast cancer (Stoll and Secreto, 1992). Androgen receptor (AR)
has been detected in almost 90% of breast cancer specimens
(Bryan et al, 1984; Soreide et al, 1992) and has been shown to be a
favourable prognostic factor for disease-free survival (Kuenen-
Boumeester et al, 1996). The AR status and levels in breast cancer
cells are positively correlated with the expression of a number of
proteins, namely prostate-specific antigen (PSA) (Hall et al, 1998)
and pepsinogen C (Balbin and Lopez. Otin, 1996) which are both
up-regulated by androgens and act as markers of cell differentia-
tion and favourable prognosis (Vozoso et al, 1995; Hahnel and
Hahnel 1996; Scorilas et al, 1999). Androgens have also been
detected in breast duct fluid (Hill et al, 1983) and in normal and
cancerous tissue (Vermeulen et al, 1986; Recchhione et al, 1995;
Secreto et al, 1996). 
The enzyme human steroid 5-a reductase type II (SRD5A2) and
AR are critical mediators of androgen action. Two isoforms of
steroid 5-a reductase are known: type I enzyme encoded by the
SRD5A1 gene, which is expressed mostly in the newborn scalp,
skin and liver. The type II enzyme which is primarily expressed in
genital skin and prostate is encoded by the SRD5A2 gene (Wigley
et al, 1994). This enzyme reduces testosterone to its more potent
form dihydrotestosterone (DHT) in the presence of NADPH (nico-
tine adenine dinucleotide phosphate; reduced form) as a cofactor
(Coffey, 1993). DHT binds to the AR and the DHT-AR complex
transactivates a number of genes with AR-responsive elements in
their promoter sequences. One such gene is PSA. In females,
breast is the major tissue capable of producing PSA. In-vitro
studies have shown that PSA production in breast tissue is up-
regulated by androgens and progestins (Zarghami et al, 1997).
Relatively high amounts of PSA protein in breast cancer tissues
are associated with steroid hormone receptor positivity, early
disease stage, and other pathological and clinical features of
favourable prognosis (Yu et al, 1995, 1996, 1998; Griniatsos et al,
1998). 
Although to-date more than 25 point mutations have been
reported in the 5 exons of the SRD5A2, only 2 of these, the codon
89 valine to leucine (V89L) and codon 49 alanine to threonine
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substitution (A49T) along with the variable length dinucleotide
TA repeats on the 3¢ untranslated region of this gene occur suffi-
ciently frequently in the population to be considered as gene poly-
morphisms (Vilchis et al, 1997). These alterations are capable of
affecting the incidence of prostate cancer (Reichardt et al, 1995).
These 2 single nucleotide changes as well as other mutations, as
shown by site-directed mutagenesis, impair the reductase activity
in one way or the other (Wigley et al, 1994; Makridakis et al,
1997; Makridakis et al, 2000). Decrease in the activity of this
enzyme in prostate cancer has been linked to favourable prognosis
(Kantoff et al, 1997). The decrease in prostate volume and PSA
level in men treated with the reductase inhibitor finasteride, lends
more credence to this idea (Gormley et al, 1992; Magklara et al,
1999, 2000; Scorilas et al, 2000). No data is available on the role
of this enzyme in breast cancer. In prostate cancer, the homozygote
VV genotype of the V89L polymorphism has been associated with
high reductase activity and high DHT levels. The homozygote LL
genotype has been associated with low reductase activity and low
DHT levels. The heterozygote VL status has been linked to inter-
mediate levels based upon studies on various ethnic groups
(Makridakis et al, 1997). Longer dinucleotide TA repeats have
been thought to decrease the reductase activity and thereby
decrease the DHT levels and PSA respectively, in prostate cancer
(Kantoff et al, 1997). No statisticlly significant difference was
found between the distribution of the TA genotypes in the breast
cancer and without breast cancer women (Bharaj et al, 2000). The
frequency of the V89L polymorphism in healthy females is the
same as in healthy males (Vilchis et al, 1997). No data is available
on the implications of these polymorphisms and 5-a-reductase
activity in breast cancer. We hypothesized that there is an
androgen-mediated contribution to the aetiology of breast cancer
and that polymorphisms in effectors and target genes of the
androgen pathway have the potential to influence breast cancer
development and prognosis. Therefore, we undertook this investi-
gation to examine the role of the V89L polymorphism in breast
cancer prognosis. 
SUBJECTS AND METHODS 
Subjects 
Tumour specimens were obtained from 151 breast cancer patients.
The patients were undergoing surgical treatment for primary breast
carcinoma at the Department of Gynecologic Oncology at the
University of Turin, Italy during the period from January 1988 to
December 1992. Tumour tissue had been frozen in liquid nitrogen
immediately after surgery. The selection criteria for the specimens
included the availability of sufficient tissue mass for extraction
and assay; the patients represented 60% of new cases of breast
cancer diagnosed and treated at the above institution during the
accrual period. This study had been approved by the Institutional
Review Board of the University of Turin. 
The median age of the patients was 54 years, with a range of 25
to 93 years. All patients had a histologically confirmed diagnosis
of primary breast cancer and received no treatment before surgery.
Modified radical mastectomy with axillary lymph node dissection
was performed on 95% of the patients. For the patients who had
axillary node dissection, the positivity rate for cancer involvement
of lymph nodes was 62%. The sizes of the tumours ranged from
0.8 to 7.0 cm and the mean and median sizes were 2.7 cm and 2.5
cm, respectively. Pathologic staging was performed according to
the Postsurgical International Union Against Cancer Tumor-Node-
Metastasis classification system (Spiessl et al, 1989). Of 150
patients for whom the stage was known, 45 (30.0%), 87 (58.0%),
7 (4.7%) and 11 (7.3%) had stages I, II, III and IV, respectively.
Histologic grade of the tumours was determined according to
criteria reported by Bloom and Richardson (1957), and was known
for 107 patients: 6 patients (5.6%) had grade I, 57 (53.3%) had
grade II and 44 patients (41.1%) had grade III. Most of the
tumours (70.2%) were of invasive ductal histologic type, whereas
the remaining tumours were invasive lobular (12.6%), ductal in-
situ (2.0%), medullary (2.6%), papillary (2.6%), tubular (2.0%),
inflammatory (2.6%), tubulo-lobular (1.3%), cribriform (2.6%),
Paget (0.7%) and muciparous (0.7%). Post-operative treatment
was known for all patients. Whereas 29% received no further treat-
ment after tumour resection, 25% were given adjuvant
chemotherapy only, 41% were treated with endocrine therapy only
and 5% were given both chemotherapy and endocrine therapy.
Disease relapse was defined as the first documented evidence of
local or regional axillary recurrence or distant metastasis. 
Information of follow-up was available for all patients and
included survival status (alive or deceased) and disease status
(disease-free or recurrence/metastasis) along with the dates of the
events and cause of death, if applicable. The relapse-free survival
time in each case was the time interval between the date of surgical
removal of the primary cancer and the date of the first documented
evidence of relapse. The overall survival time was the time
interval between the date of surgery and the date of death, or
the date of last follow-up for those who were alive at the end of the
study. During their respective follow-up periods, 56 patients
(37.1%) developed cancer relapse and 39 (25.8%) died. 
Extraction of DNA 
DNA was extracted from tissues using the Qiagen tissue DNA
extraction kit (Qiagen, Chatsworth, CA, USA). Approximately 25
mg of tissue was used to extract the DNA. The breast tissue which
contained more than 70% tumour cells, as determined by histolog-
ical examination, was pulverized into a fine powder and stored
until used at 280˚C. Briefly, after the lysis of cells, the DNA was
entrapped onto the silica membrane, washed and eluted in a buffer
solution. DNA was quantified by absorbance measurements at 260
nm and stored at 4˚C until analysis. 
Amplification of the V89L polymorphism region by PCR 
Two paired primer sequences flanking the V89L polymorphism
region were used and their sequences were as follows: 5¢-GCA
GCG GCC ACC GGC GAG G-3¢ and 5¢-AGC AGG GCA GTG
CGC TGC ACT-3¢. 
The oligonucleotides were designed using the computer soft-
ware Oligo 5.0 (National Biosciences Inc, Plymouth, MN),
according to the SRD5A2 gene sequence deposited in Genebank
by Labrie et al (1992), accession # L03843. PCR amplification
was performed in a final volume of 25 ml, containing approx-
imately 100–150 ng of template DNA, 10 mM PCR buffer, 2.5
units of Taq polymerase (Roche Molecular Systems), 250 mM of
deoxynucleoside triphosphates, 2.25 mM MgCl2 and 1 mM of each
primer. The thermal cycling consisted of a 30 s denaturation at
94˚C, annealing at 65˚C for 30 s and extension at 68˚C for 1 min,
and it was repeated for 30 cycles. The final extension was at 68˚C
for 7 min. The PCR was initiated by a 5 min denaturation at 95˚C.762 A Scorilas et al 
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The success of PCR was verified by running 8 ml of the amplified
product on a 2% agarose gel containing ethidium bromide. 
DNA sequencing 
The PCR product was sequenced on a Visible Genetics automated
sequencing apparatus (Visible Genetic Inc; Toronto, Canada). The
sequencing primers were labelled at the 5¢-end with the fluorescent
dye Cy 5.5. The sequencing primers used were as follows: 5¢-GCA
ACG AGC ACA CGG AGA GC-3¢ and 5¢-GCA GGG CAG TGC
GCT GCA CT-3¢. The sequencing protocol and the cycle
sequencing conditions used were as follows: Initial denaturation
for 5 min at 95˚C, then cycling denaturation at 94˚C for 1 min;
annealing/extension at 65˚C for 1 min, for 35 cycles, followed by a
final extension for 5 min at 65˚C. The sequencing was carried out
as previously described (Bharaj et al, 1998). Both strands were
sequenced. 
Fragment analysis of dTA repeat lengths 
The TA repeat lengths were PCR-amplified using fluorescently
labelled Cy 5.5 primers. Fragment analysis was carried out on a
Visible Genetics Automated DNA Sequencer as previously
described (Bharaj et al, 1999). 
Steroid hormone receptor analyses 
Tumour specimens (n = 148) were pulverized in liquid nitrogen,
homogenized in buffer, and the cytosolic fractions were obtained
by ultracentrifugation and quantified for steroid hormone receptors
as described elsewhere (Dressler et al, 1988). The results of the
dual ligand-binding assay, in which dextran-coated charcoal was
used to separate bound from free ligand, were interpreted by
Scatchard analysis (Scatchard, 1949). Protein concentrations of the
cytosols were determined by the Lowry method (Lowry et al,
1951). Tumours with ER and PR concentrations below or equal to
10 fmol mg-1 protein were considered as receptor negative,
whereas tumours with receptor concentrations above such values
were considered positive, as followed previously (Reiher et al,
1987; Alexieva-Figusch et al, 1988). Based on these cutoffs, 99
(67.3%) and 93 (63.7%) of 147 and 146 breast carcinomas were
ER- and PR-positive, respectively. 
PSA immunoassay 
The determination of total PSA concentration in all samples was
performed by an ultrasensitive time-resolved immunofluorometric
assay as described elsewhere (Ferguson et al, 1996). The PSA
assay has a detection limit of 0.001 ng ml21. All specimens were
measured in duplicate. The values used for statistical analysis were
adjusted for total protein content and are expressed as ng of PSA
per g of total protein in the cytosolic extracts. 
Statistical analysis 
Associations between V89L genotypes and other categorical vari-
ables were analysed using the chi-square (c2) test. ER and PR
values were categorized into positive and negative status as
described above. The cutoff value for tumour size was 2 cm. Lymph
node status was either positive (histological evidence of tumour
extension to one or more lymph nodes) or negative. Age was
categorized into three groups: less than 45 years, 45 to 55 years and
greater than 55 years. Kruskal-Wallis test was used for statistical
evaluation of differences in PSA values between 3 groups of V89L
genotypes. In this analysis, PSA was used as a continuous variable.
Survival analyses were performed by constructing Kaplan–Meier
DFS and OS curves (Kaplan and Meier, 1958), whereas differences
between curves were evaluated by the log-rank test. Cox regression
analyses using the SAS statistical software (SAS Institute, Cary,
NC) was used to calculate the RR and 95% CI. Only patients for
whom the status of all variables was known were included in the
multivariate models, which incorporated V89L genotypes and all
other variables for which the patients were characterized. 
RESULTS 
Distribution of V89L alleles and their relationship with
TA length repeats 
Figure 1 represents sequencing chromatograms of the polymor-
phism in the SRD5A2 gene, showing the base change at codon 89.
The sequencing was carried out in 144 breast tumours. Among
these tumours, 77 (53.5%) had GTA nucleotides at codon 89 (VV
alleles), 53 (36.8%) were heterozygous with GTA/CTA codons
(VL alleles) and the remaining 14 (9.3%) were homozygous for
CTA codon (LL alleles). No other point mutations, insertions, or
deletions were detected in the DNA sequences flanking the codon
89 region of the SRD5A2 gene. The distribution of TA repeat
lengths in the same DNAs is shown in Table 1. 
Table 1 also shows the relationship between V89L genotypes
and the dinucleotide TA repeat lengths: TA(0), no repeats present;
TA(9), 9 TA repeats. It is evident that 70% of the TA(0)/TA(9)
heterozygotes are associated with homozygous VV allele, 30%
with VL allele and none with the homozygous LL allele. All TA(9)
homozygotes are associated with VV allele. All tumours with LL
allele have TA(0) genotype. All these differences are statistically
significant (P < 0.001). TA(0) repeats were only found in VV, LL
homozygotes as well as in VL heterozygotes. TA(9) repeat lengths
were only found in VV homozygotes and were totally absent in the
LL homozygotes. Thus, the TA(9) repeat appears to be linked to
the VV genotype. Absence of (TA)9-LL genotype might indicate
linkage disequilibrium. 
Associations of V89L genotypes to other prognostic
variables 
The distributions of V89L genotypes – VV, VL and LL – between
subgroups of patients differing by age, tumour size, nodal status,
grade, histological type, disease stage, ER status, PR status and
adjuvant treatment administered were examined by the chi-square
test (Table 2). LL genotype was found more frequently in younger
Table 1 Relationship between the V89L and TA polymorphisms of the 
5a-reductase gene 
TA genotypes
V89L genotypes (%) 
VV VL LL Total
P value 
TA(0) 42 (43.3) 41 (42.3) 14 (14.5) 97 
TA(0)/(9) 28 (70.0) 12 (30.0) 0(0.0) 40 P < 0.001 
TA(9) 7 (100.0) 0 (0.0) 0 (0.0) 7 
Total 77 53 14 144 patients (below 45 years) as well as in grade III patients (P = 0.008
and  P = 0.037 respectively). Differences in tumour tissue PSA
concentrations between the V89L genotypes were found to be
statistically significant by the Kruskal-Wallis test (P = 0.030)
(Figure 2). Statistically significant associations between V89L
genotype and tumour size, nodal status, stage, histological type and
steroid hormone receptors were not observed. In the same analysis,
V89L genotypes were shown not to differ between patients who
received different post-operative treatment modalities. 
V89L polymorphism and breast cancer survival
Univariate and multivariate Cox regression models were de-
veloped to evaluate the effect of V89L genotypes on DFS and OS
for breast cancer patients (Table 3). These regression models
demonstrated an increase in risk for relapse and death in patients
with the LL genotype compared to those with the VV or VL geno-
type. The unfavourable DFS and OS rate of LL patients relative to
those of VV or VL patients is also shown by Kaplan–Meier
survival analysis (Figure 3). In the multivariate analysis of V89L
genotypes, the Cox regression models were adjusted for age, nodal
status, tumour size, and ER and PR status, all of which were used
as categorical variables, except tumour size, which was used as a
continuous variable. 
DISCUSSION 
There is evidence that androgens play a role in the development
and progression of breast cancer. The product of the 5-a-reductase
activity, DHT, is a more potent androgen, with higher affinity for
the AR than its precursor, TT. DHT acts as a mitogen and can bind
to the AR and transactivate a number of androgen responsive
genes (Coffey, 1993). SRD5A2 is one such gene that is regulated
by androgens. 
A prevalent polymorphism of a valine to leucine substitution at
codon 89 in exon 1 of the SRD5A2 gene has been reported in
males and females (Vilchis et al, 1997). The frequency of this
polymorphism is not different between males and females. This
V89L substitution has been reported to influence the activity of the
reductase enzyme (Wigley et al, 1994). In this study, we examined
this polymorphism in DNA from breast tumours. The most
common allele was homozygous valine (GTA) (53.5%), followed
by heterozygous valine/leucine (GTA/CTA) (37%); the remaining
patients were homozygous for leucine (CTA) (10%). No other
substitution flanking this polymorphism was detected in any of the
breast tumours, including the codon 91 substitution of thymine
(TAC) for guanine (GAC), as reported by Wilson et al (1993).
Since the V89L polymorphism alters the coding region of the
protein, in-vitro kinetic studies (Ross et al, 1992) have shown that
the leucine variant (LL) decreases the activity of the 5-a reductase
enzyme by almost a third, in comparison to its valine counterpart
(VV). This relationship holds in-vivo too and affects PSA expres-
sion (Makridakis et al, 1997). Makridakis et al investigated the
biochemical and pharmacogenetic dissection of the SRD5A2
enzyme by analysing 10 missense substitutions and 3 double muta-
tions, all of which are naturally found in humans. It was reported
that all except one of these mutations are capable of significantly
influencing the enzyme activity (Makridakis et al, 2000). 
The results shown in Figure 2 indicate differences in PSA
concentration of breast cytosolic extracts in patients with VV and
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Figure 1 Sequence analysis of SRD5A2 gene. Exon 1 was amplified from
genomic DNA by PCR with primers 1F (5¢-GCA ACG AGC ACA CGG AGA
GC- 3¢) and 1R (5¢-GCA GGG CAG TGC GCT GCA CT-3¢). The sequencing
primers were labelled at the 5¢-end with the fluorescent dye Cy 5.5. The
amplified fragments were subjected to nucleotide sequence with visible
genetics automated sequencing machine (Visible Genetic Inc; Toronto,
Canada). The chromatograms A, B and C show the V89V (GTA
homozygous), V89L (GTA/CTA heterozygous) and L89L (CTA homozygous)
respectively 
1.30
1.20
1.10
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
Genotypes in breast cancer patients
VV V/L LL
N=14
n=77
n=53
P=0.030
Figure 2 Relationship between V89L genotypes and breast tumour extract
PSA concentrations. The median values were 0.099 ng mg21, 0.076 ng mg21
and 0.036 ng mg21 protein for VV, VL and LL genotypes, respectively; 
P = 0.030, as determined by the Kruskal-Wallis test 764 A Scorilas et al 
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Table 2 Relationship between V89L genotypes and clinical/pathological features of breast cancer 
No. of patients (%) 
Features Total VV VL LL P valuea
Age (years) 
<45 38 18 (50.0) 9 (25.0) 9 (25.0) 0.008 
45–55 38 18 (51.4) 15 (42.9) 2 (5.7) 
>55 75 41 (56.2) 29 (39.7) 3 (4.1) 
Tumour size (cm) 
<2 43 20 (48.8) 18 (43.9) 3 (7.3) 0.51 
³2 105 55 (55.0) 34 (34.0) 11 (11.0) 
Nodal status 
Negative 55 28 (53.8) 20 (38.5) 4 (7.7) 0.85 
Positive 88 45 (52.9) 31 (36.5) 9 (10.6) 
Gradeb
I–II 63 36 (59.0) 22 (36.1) 3 (6.6) 0.037 
III 44 23 (53.5) 11 (26.2) 9 (16.7) 
Histology 
Ductal 106 58 (57.4) 32 (31.7) 11 (10.9) 0.228 
Lobular 19 9 (50.0) 9 (50.0) 0 (0.0) 
Other 26 10 (40.0) 12 (48.0) 3 (12.0) 
Stagec
I 45 25 (58.1) 13 (30.2) 5 (11.6) 0.69 
II 87 41 (50.0) 34 (41.5) 7 (8.5) 
III–IV 18 11 (61.1) 5 (27.8) 2 (11.1) 
ER statusd
Negative 48 25 (54.3) 15 (32.6) 6 (13.0) 0.49 
Positive 99 50 (53.2) 37 (39.4) 7 (7.4) 
PR statusd
Negative 53 30 (61.2) 16 (32.7) 3 (6.1) 0.33 
Positive 93 44 (48.9) 36 (40.0) 10 (11.1) 
Adjuvant treatment 
None 45 22 (51.2) 16 (37.2) 5 (11.6) 0.09 
Tamoxifen 62 31 (51.7) 27 (45.0) 2 (3.3) 
Chemotherapy6 tamoxifen 44 24 (58.5) 10 (24.4) 7 (17.1) 
ac2 test. bBloom-Richardson grading system. cTNM system. dCutoff point: 10 fmol mg21 protein. 
Table 3 Association between V89L genotypes and breast cancer survival 
Disease-free survival Overall survival 
Variable RRa (95% CI)b P value RRa(95% CI)b P value 
Univariate analysis 
VV 1.00 1.00 
VL 1.15 (0.64–2.09) 0.62 1.18 (0.56–2.46) 0.65 
LL 2.65 (1.23–5.71) 0.013 3.06 (1.25–7.45) 0.014 
Multivariate analysisc
VV 1.00 1.00 
VL 1.04 (0.55–1.96) 0.90 1.09 (0.49–2.43) 0.81 
LL 1.91 (0.79–4.58) 0.14 2.55 (0.90–7.27) 0.078 
aRelative risk (RR) estimated from Cox proportional hazard regression model. bConfidence interval of
the estimated RR. cMultivariate models were adjusted for lymph nodes status; tumour size; patient
age; ER and PR expression. Codon 89 polymorphism of the 5a-reductase gene in breast cancer 765
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LL allele, respectively, the former having a significantly higher
expression. The VL allele showed an intermediate PSA expression
which was also significantly higher than that observed in the LL
allele. This could be explained by the fact that the GTA genotype
encodes for a more active reductase enzyme than the CTA geno-
type (Kantoff et al, 1997), leading to an increased production of
DHT. Higher levels of this androgen up-regulate PSA expression.
The VV allele is, for the same reason, related to a higher risk of
prostate cancer. PSA is a favourable prognostic factor in breast
cancer and patients with elevated concentrations in their tumour
extracts, have reduced risk of cancer relapse and death (Yu et al,
1995, 1996, 1998; Griniatsos et al, 1998). Besides PSA, two other
proteins expressed in breast tumour tissues, pepsinogen C and
pS2, have also been shown to be favourable prognostic indicators
(Foekens et al, 1993; Ardavanis et al, 1997; Scorilas et al, 1999,
2000). These proteins are associated with steroid hormone
receptor positivity and/or hormonal responsiveness. Our data
suggest that the VV alleles, which are related to higher levels of
PSA in breast cancer cytosols, are associated with decreased risk
in terms of overall survival and relapse (Figure 3). 
Studies of prostate cancer have reported that the lengths of the
TA polymorphic repeats can influence the 5-a reductase activity.
Longer repeats in Caucasians have been linked to down-regulation
of the enzyme activity, thereby lowering the DHT production with
a resultant decrease in PSA expression and hence lower cancer
risk (Kantoff et al, 1997). In contrast, in breast tumours, the longer
repeats seem to be associated with enhanced 5-a reductase activity
which results in higher PSA expression. It was found that longer
TA repeats are associated with breast tumours which have higher
PSA content. More specifically, there is a positive relationship
between (TA0)/(TA)9 or (TA)9 genotype and PSA levels. Longer
TA repeats appear to be favourable prognostic indicators in breast
cancer patients (Bharaj et al, 2000). This is supported also by the
data in Table 1 which show that 70% of the breast tumours with
heterozygous TA(0)/TA(9) repeat lengths are associated with VV
alleles, 30% with VL alleles and none with LL alleles. All
homozygous TA(9) repeats detected in these tumours are associ-
ated with the VV alleles (Table 1). The TA repeats occur in the
non-coding region of the SRD5A2 gene and do not affect the func-
tion of the resulting protein. However, there is evidence that such
TA rich sequences in the 3¢ untranslated region of other genes are
associated with mRNA instability (Zubiaga et al, 1995). Somatic
mutations at the 3¢ untranslated region of the SRD5A2 locus which
lead to loss of heterozygosity and microsatellite instability of this
marker have also been reported (Akalu et al, 1999). Increase in TA
lengths may therefore, be associated with relative messenger insta-
bility and decreased levels of the 5-a reductase activity. Tumours
with longer (homozygous TA(9) and heterozygous TA(0)/TA(9))
repeat lengths, when compared to those with shorter TA(0) alleles
by Cox regression analysis, showed a 40% reduction in risk for
relapse (Bharaj et al, 2000). This relationship also concurs with the
decreased risk observed in the VV alleles (Figure 3) to which the
TA(9) repeats appear to be linked (Table 1).
Based on these data, it may be speculated that the VV allele and
the longer dinucleotide TA repeat length in breast cancer could be
associated with a favourable prognosis and a later onset of the
disease (Table 2). This study also reiterates the importance of
androgens in the development and progression in breast cancer.
Since these 2 polymorphisms are heritable, any resultant effect is
present throughout the life. Even small changes in the 5-a reduc-
tase activity and the subsequent effect on DHT production can
have a significant effect on risk for breast cancer. However, it
would be more meaningful if the tissue reductase enzyme activity
and DHT levels are measured simultaneously in parallel with these
polymorphisms, in order to directly address the biological signif-
icance of these polymorphisms. No such data are available to date
on breast cancer. Our results raise the possibility that genetic alter-
ations in the 5-a reductase activity may have a role in modifying
breast cancer incidence rates, age of onset and aggressiveness 
of breast cancer. If these findings are confirmed, they may 
have important implications for breast cancer prevention and
possibly treatment. Further studies will be required to further
determine the role of androgens in breast cancer pathogenesis and
progression. 
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